Camp4 Therapeutics

The company's core focus is on developing a new class of programmable medicines designed to upregulate gene expression. This approach targets regulatory RNAs (regRNAs), which are non-protein-coding molecules that control the expression of nearby genes. By modulating these regRNAs with proprietary antisense oligonucleotide (ASO) drug candidates, called RNA Actuators, Camp4 aims to increase the output of specific proteins. This method holds the potential to treat a wide array of genetic diseases where a modest increase in protein levels could result in significant therapeutic benefits, particularly in haploinsufficient diseases where a patient has only one functional copy of a gene.

Camp4's business model centers on the discovery and development of this therapeutic pipeline, funded through substantial venture capital and strategic partnerships with larger pharmaceutical companies. The company has raised a total of $180 million over four funding rounds, with notable investors including Andreessen Horowitz, Polaris Partners, and Enavate Sciences. Its revenue is generated through upfront payments, milestone achievements, and potential future royalties from collaborations, such as its research agreement with BioMarin Pharmaceutical. This partnership allows BioMarin to select targets identified by Camp4's platform for further development, providing Camp4 with both capital and drug development expertise.

The company’s proprietary RNA Actuating Platform (RAP™) systematically maps these regulatory RNAs across different cell types, enabling the rapid identification of druggable targets and the generation of therapeutic candidates. Initially, Camp4 is concentrating on diseases of the central nervous system and the liver. Its lead program, CMP-CPS-001, is in Phase 1 clinical trials for treating urea cycle disorders (UCDs), a group of severe inherited metabolic diseases. Another key pipeline product is being developed for SYNGAP1-related disorders. Following a strategic pivot in 2020 to focus solely on this regRNA approach, the company has positioned itself to address hundreds of potential diseases.